Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.119
Neutral
RSI(14)
50.887
Neutral
STOCH(KDJ)(9,3,3)
32.525
Sell
ATR(14)
0.736
High Vlolatility
CCI(14)
-37.905
Neutral
Williams %R
67.593
Sell
TRIX(12,20)
0.652
Sell
StochRSI(14)
0.000
Sell
Search
Neuraxis Inc
NRXSAdd to Watchlist
7.870USD
-0.470-5.63%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
90.11MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Neuraxis Inc
Currency: USD Updated: 2026-05-15Key Insights
Neuraxis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 111 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neuraxis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Neuraxis Inc Highlights
StrengthsRisks
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 45.09% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.57M.
Undervalued
The company’s latest PE is -9.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.57M shares, decreasing 17.72% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Neuraxis Inc is 5.87, ranking 182 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.61M, representing a year-over-year increase of 79.52%, while its net profit experienced a year-over-year increase of 21.72%.
Score
Financials
7.94
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.12
Operational Efficiency
2.84
Growth Potential
4.37
Shareholder Returns
7.08
Neuraxis Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Neuraxis Inc is 7.60, ranking 73 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -9.93, which is -100.00% below the recent high of 0.00 and -6.10% above the recent low of -10.53.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 111/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Neuraxis Inc is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
116
Total
6
Median
9
Average
Company name
Ratings
Analysts
Neuraxis Inc
NRXS
2
Medtronic PLC
MDT
33
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
31
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Neuraxis Inc is 7.28, ranking 54 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 9.18 and the support level at 6.71, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
8.110
Sell
MA10
8.335
Sell
MA20
7.958
Sell
MA50
7.373
Buy
MA100
6.075
Buy
MA200
4.396
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Neuraxis Inc is 3.00, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 22.68%, representing a quarter-over-quarter increase of 18.35%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neuraxis Inc is 1.86, ranking 173 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+39.53%
240-Day Volatility
+90.77%
Return
Best Daily Return
60 days
+11.95%
120 days
+25.16%
5 years
--
Worst Daily Return
60 days
-14.10%
120 days
-14.10%
5 years
--
Sharpe Ratio
60 days
+2.48
120 days
+3.32
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+39.53%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+4.84
3 years
--
5 years
--
Skewness
240 days
+0.78
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+90.77%
5 years
--
Standardised True Range
240 days
+4.19%
5 years
--
Downside Risk-Adjusted Return
120 days
+558.01%
240 days
+558.01%
Maximum Daily Upside Volatility
60 days
+66.39%
Maximum Daily Downside Volatility
60 days
+56.97%
Liquidity
Average Turnover Rate
60 days
+1.96%
120 days
+2.87%
5 years
--
Turnover Deviation
20 days
-56.44%
60 days
-60.98%
120 days
-42.92%
Peer Comparison
Healthcare Equipment & Supplies
Neuraxis Inc
NRXS
6.15 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
